121181-53-1

Basic information

• Product Name: FILGRASTIM
• Synonyms: FILGRASTIM;n-l-methionyl-colony-stimulatingfactor(humanclone1034;Colony-stiMulating factor (huMan clone 1034), N-L-Methionyl- (9CI)
• CAS NO: 121181-53-1
• Molecular Formula: W99
• Molecular Weight: 0
• Mol File: 121181-53-1.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Storage Temp.: -70°C
• CAS DataBase Reference: FILGRASTIM(CAS DataBase Reference)
• NIST Chemistry Reference: FILGRASTIM(121181-53-1)
• EPA Substance Registry System: FILGRASTIM(121181-53-1)

Safety Data

• Hazardous Substances Data: 121181-53-1(Hazardous Substances Data)

Usage

Description

FILGRASTIM is a recombinant human granulocyte colony stimulating factor (G-CSF) that functions as a hematopoietic stimulant and is used to treat neutropenia.

Uses

Used in Antineutropenic Therapy:
FILGRASTIM is used as a hematopoietic stimulant for treating neutropenia, a condition characterized by an abnormally low count of neutrophils, a type of white blood cell essential for fighting infections.
Used in Cancer Treatment:
FILGRASTIM is used as an adjunct to cancer chemotherapy for patients with non-myeloid malignancies. It helps reduce the duration of chemotherapy-induced neutropenia by promoting the differentiation of immature leucocytes into neutrophils, which in turn decreases the incidence and length of infections.
Used in Bone Marrow Transplants:
FILGRASTIM is used to stimulate the production of neutrophils in patients undergoing bone marrow transplants, aiding in the faster recovery of the immune system post-transplant.
Used in Myelodysplastic Syndromes:
FILGRASTIM is used as a treatment for myelodysplastic syndromes, a group of disorders caused by poorly formed blood cells or ones that don't work properly. It helps improve blood cell production and function.
Used in Febrile Neutropenia:
FILGRASTIM is used to manage febrile neutropenia, a condition where patients experience fever due to a severely low neutrophil count, often as a side effect of chemotherapy.
Chemical Properties:
FILGRASTIM is a clear, colorless, or slightly yellowish liquid.
Brand Name:
The brand name for FILGRASTIM is Neupogen, which is manufactured by Amgen.

Originator

Amgen (U.S.A.)

Indications

Filgrastim (Neupogen) is a human recombinant granulocyte colony–stimulating factor (rG-CSF) produced using recombinant DNA technology. It acts on precursor hematopoietic cells in the bone marrow by binding to specific receptors that stimulate cellular proliferation and differentiation into neutrophils. It also enhances some neutrophil functions, including phagocytosis and antibody-dependent killing.

Clinical Use

Filgrastim, G-CSF, Neupogen, stimulates the proliferation ofgranulocytes (especially neutrophils) by mobilizinghematopoietic stem cells in the bone marrow. The native protein is glycosylated.Filgrastim selectively stimulates proliferation and differentiationof neutrophil precursors in the bone marrow. Thisleads to the release of mature neutrophils into the circulationfrom the bone marrow. Filgrastim also affects mature neutrophilsby enhancing phagocytic activity, priming the cellularmetabolic pathways associated with the respiratoryburst, enhancing antibody-dependent killing, and increasingthe expression of some functions associated with cell surfaceantigens.In patients receiving chemotherapy with drugs such ascyclophosphamide, doxorubicin, and etoposide, the incidenceof neutropenia accompanied by fever is rather high.Administration of G-CSF reduces the time of neutrophilrecovery and duration of fever in adults with acute myelogenousleukemia. The number of infections, days thatantibiotics are required, and duration of hospitalization arealso reduced.

Clinical Use

Filgrastim is used to accelerate recovery of neutrophils after chemotherapy, both to prevent infections and to shorten the duration of neutropenia in patients in whom infections have developed.

Side effects

The drug is generally well tolerated, with the major adverse reaction being mild to moderate bone pain secondary to stimulation of bone marrow proliferation.

Veterinary Drugs and Treatments

Filgrastim may be of benefit in treating neutropenias in dogs or cats when the intrinsic response to endogenously produced cytokines is thought to be inadequate and there is evidence that there are precursors in the bone marrow available. Because of the drug’s cost and lack of good evidence for its efficacy in reducing mortality versus using antibiotic therapy alone, its use in small animal medicine is somewhat controversial.

Drug interactions

Potentially hazardous interactions with other drugs Cytotoxics: neutropenia possibly exacerbated with capecitabine, fluorouracil and tegafur.

Metabolism

Filgrastim is primarily eliminated by the kidney and neutrophils/neutrophil precursors; the latter presumably involves binding of the growth factor to the G-CSF receptor on the cell surface, internalisation of the growth factor-receptor complexes via endocytosis, and subsequent degradation inside the cells